Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Deferred Tax Liability (2024 - 2025)

Spero Therapeutics' Non-Current Deferred Tax Liability history spans 2 years, with the latest figure at $388000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 52.45% year-over-year to $388000.0; the TTM value through Dec 2025 reached $388000.0, down 52.45%, while the annual FY2025 figure was $388000.0, 52.45% down from the prior year.
  • Non-Current Deferred Tax Liability reached $388000.0 in Q4 2025 per SPRO's latest filing, down from $816000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $816000.0 in Q4 2024 to a low of $388000.0 in Q4 2025.